Firalis SA
10
4
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
Role: lead
Validation of the Stability of Diagnostic Biomarkers on Healthy Volunteers
Role: lead
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Role: lead
A Study of NTRX-07 in Participants With Alzheimer's Disease
Role: collaborator
A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis
Role: lead
ADDIA Proof-of-Performance Clinical Study
Role: collaborator
HeartLinc, a Study With AMI Patients Undergoing PCI
Role: lead
Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection
Role: lead
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study
Role: collaborator
Prospective Study With AMI Patients Undergoing PCI
Role: lead
All 10 trials loaded